The Company also announced a presentation on JUNE 10 by Dr. Werner at the LD Micro Virtual Invitational XI:
LD Micro Virtual Invitational XI
Date: Thursday, June 10, 2021
Time: 11:30am ET
Dr. Werner will present and discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the Company's lead asset being developed for the treatment of Parkinson's disease in the brain and gastrointestinal tract.
Webcasts of the presentations will be available for on-demand viewing under "News & Events" in the Investors section of the Company's website, www.inhibikase.com. An archived replay of the webcasts will be available for approximately 30 days following each event.
About Inhibikase (www.inhibikase.com) $IKT
News 
Market Data 
Discover 
AI
